Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

Table 4

HPD according to ROC curves.

Tumor types	Characteristic tumor markers	Cut-off values	Sensitivity	Specificity	value
Lung squamous carcinoma	CYFRA211/NSE/SCC	12%	100.0%	78.8%	0.022
Lung adenocarcinoma	CEA/CA125	29%	87.5%	65.2%	<0.01
Colorectal cancer	CA125/CA724/CA199/CEA	49%	100.0%	93.7%	<0.01
Pancreatic cancer	CA199	167%	85.7%	94.1%	<0.01
Cholangiocarcinoma	CA199	126%	100.0%	91.7%	0.034

HPD: hyperprogressive disease; ROC: receiver operating characteristic.